NCT04321512 Study of Circulating Monocytes in Patients With Ischemic Vascular Disease
| NCT ID | NCT04321512 |
| Status | Recruiting |
| Phase | — |
| Sponsor | UConn Health |
| Condition | Myocardial Infarction |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2013-12-01 |
| Primary Completion | 2027-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2013-12-01 with a primary completion date of 2027-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research study is to discover the functions of circulating white blood cells, called monocytes, and associated circulating substances in heart attack and ischemic stroke patients. Ischemic Strokes (clots) occur as a result of an obstruction within a blood vessel supplying blood to the brain. A type of monocyte carrying a surface marker called "P2X4" helps the immune system sense and respond to danger signals from the body such as heart muscle and brain tissue injuries. The researchers expect to learn more about how these monocyte cells react to heart and brain tissue injury, and how the cells may then produce proteins or other chemical substances which promote the healing of heart muscle after heart attack and brain tissue after an ischemic stroke.
Eligibility Criteria
Inclusion Criteria: * STEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of STEMI. * NSTEMI Patients: Men and women aged 18 years and over, with symptoms, physical signs and ECG changes characteristic of NSTEMI. * Stable CAD Patients: men and women aged 18 years and older with coronary artery disease proven by prior MI history, angiography or stress test but without any unstable angina or acute coronary syndrome. * Ischemic Stroke Patients: Men and women aged 18 years and over, with symptoms, physical signs and CT/MRI changes characteristic of ischemic stroke. * Healthy Controls: Men and women aged 18 years and over, without heart failure, coronary disease, hypertension, diabetes or other chronic diseases. Control subjects will be recruited from within the community of UConn Health via advertisement. Exclusion Criteria: * Subjects who are unable to give informed consent (with the exception of the ischemic stroke arm patients, see Protocol Design below) and pregnant subjects. * Subjects who had any history of embolic, ischemic or hemorrhagic stroke within the last 12 months.
Contact & Investigator
Bruce Liang, MD
PRINCIPAL INVESTIGATOR
UConn Health
Frequently Asked Questions
Who can join the NCT04321512 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Myocardial Infarction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04321512 currently recruiting?
Yes, NCT04321512 is actively recruiting participants. Contact the research team at fshah@uchc.edu for enrollment information.
Where is the NCT04321512 trial being conducted?
This trial is being conducted at Farmington, United States.
Who is sponsoring the NCT04321512 clinical trial?
NCT04321512 is sponsored by UConn Health. The principal investigator is Bruce Liang, MD at UConn Health. The trial plans to enroll 300 participants.